Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financi...( 2007 (unaudited) ...),Health

Date:2/27/2009

, 2007 (unaudited) Actual (GAAP) Adjustments Adjusted Net sales $1,085,608 - $1,085,608 Costs and expenses: Cost of sales 217,369 - 217,369 Selling, general and administrative 411,869 (12,397) (1) 399,472 Research and development 138,255 (36,391) (2) 101,864 Impairment of other intangible assets 889 (889) (3) - Operating income 317,226 49,677 366,903 Interest expense 117 - 117 Interest and other income, net (36,141) - (36,141) Income before income taxes 353,250 49,677 402,927 Income taxes 125,810 19,001 (4) 144,811 Net income $227,440 $30,676 $258,116 Diluted earnings per share $1.69 $1.92 Diluted weighted average shares 134,525 134,548 Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations: (1) To exclude stock-based compensation. (2) To exclude stock-based compensation ($1,531) and upfront and milestone payments to partners ($34,860). (3) To exclude impairment of other intangible assets. (4) To reflect the tax effect of the pre-tax adjustments above at the applicable tax rates.

               Reconciliation of Projected GAAP Diluted Earnings Per
               Share to Adjusted Diluted Earnings Per Share Guidance

    2009 Outlook (unaudited)

                                                            Year Ended
                                                        December 31, 2009

    Projected GAAP diluted
     
'/>"/>
SOURCE  Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Related medicine news :

1. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
2. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
3. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
4. Endo Pharmaceuticals Appoints William Montague to Board of Directors
5. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
6. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
7. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
8. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
9. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
10. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
11. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results